New Phase I trial of selective HDAC6 inhibitor in myeloma to commence

Acetylon Pharmaceuticals Inc., the US-based company, has announced it is starting a Phase 1a/b dose escalation trial of its drug candidate ACY-241 as a monotherapy and in combination with ImnovidĀ® (pomalidomide) and low-dose dexamethasone for relapsed and/or refractory myeloma patients. ACY-241 is a selective inhibitor of the intracellular enzyme histone deacetylase 6 (HDAC6) which works…

Details